Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3A | P31941 | 3/20 | 1.00 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13995847 | 0.84 | APOBEC3A (0.73) | APOBEC3AAPOBEC3GKDM4EHTR2AHTR2C | |
| SCHEMBL14249152 | 0.84 | APOBEC3A (0.73) | APOBEC3AAPOBEC3GKDM4EHTR2AHTR2C | |
| SCHEMBL4312244 | 0.80 | APOBEC3A (0.67) | APOBEC3AAPOBEC3GKDM4ETDP1HTR2A | |
| SCHEMBL4250069 | 0.80 | APOBEC3A (0.67) | APOBEC3AAPOBEC3GKDM4ETDP1HTR2A | |
| SCHEMBL17883352 | 0.80 | APOBEC3A (0.67) | APOBEC3AAPOBEC3GKDM4EHTR2AHTR2C | |
| SCHEMBL17321385 | 0.80 | APOBEC3A (0.67) | APOBEC3AAPOBEC3GKDM4ETDP1HTR2A | |
| SCHEMBL7048077 | 0.79 | APOBEC3A (0.65) | APOBEC3AAPOBEC3GKDM4EHTR2AHTR2C | |
| SCHEMBL17460426 | 0.78 | APOBEC3A (0.62) | APOBEC3AAPOBEC3GHTR2AHTR2CGFER | |
| SCHEMBL4794765 | 0.77 | APOBEC3A (0.61) | APOBEC3AAPOBEC3GKDM4EHTR2AHTR2C | |
| SCHEMBL4428625 | 0.77 | APOBEC3A (0.61) | APOBEC3AAPOBEC3GKDM4ETDP1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| US-20250161307-A1 | PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-22 | — | — | US | disclosed |
| WO-2025087365-A1 | METTL3 INHIBITOR | 杭州邦顺制药有限公司 | 2025-05-01 | — | — | WO | disclosed |
| CN-119899188-A | METTL3 inhibitors | 杭州邦顺制药有限公司 | 2025-04-29 | — | — | CN | disclosed |
| EP-4540242-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A | Plexium, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-4536653-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | Eisai R&D Management Co., Ltd. (JP) | 2025-04-16 | — | — | EP | disclosed |
| CN-119654318-A | Compounds and pharmaceutical compositions for degrading SWI/SNF-associated matrix-associated actin-dependent chromatin subfamily A modulators | 普莱克斯姆公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-4469454-A1 | PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE | Janssen Pharmaceutica NV (BE) | 2024-12-04 | — | — | EP | disclosed |
| WO-2010096115-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROL OF HEPATITIS C VIRAL INFECTIONS | APATH, LLC (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20100099683-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-22 | — | — | US | disclosed |
| US-20100099683-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-22 | — | — | US | disclosed |
| US-20100041638-A1 | Chemical Compounds 293 | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | US | disclosed |
| WO-2009144494-A1 | PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PDE4 MEDIATED DISEASE STATES | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | WO | disclosed |
| EP-1309565-B1 | HETEROCYCLIC MUTILIN ESTERS AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2008-04-09 | — | — | EP | disclosed |
| US-6878704-B2 | Heterocyclic mutilin esters and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-04-12 | — | — | US | disclosed |
| US-20040058937-A1 | Heterocyclic mutilin esters and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-25 | — | — | US | disclosed |
| EP-1309565-A1 | HETEROCYCLIC MUTILIN ESTERS AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002012199-A1 | HETEROCYCLIC MUTILIN ESTERS AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058937-A1 | Heterocyclic mutilin esters and their use as antibacterials | MLN, MSH2, MRPL21 | APOBEC3A 3459/4885APOBEC3G 3856/4885KDM4E 4142/4885 |
| US-20100041638-A1 | Chemical Compounds 293 | PDE4B, PDE4A, PDE3B | APOBEC3A 4668/4885APOBEC3G 4524/4885KDM4E 778/4885 |
| US-20100099683-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | LIG1, LIG4, LIG3 | APOBEC3A 383/4885APOBEC3G 439/4885KDM4E 1696/4885 |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | APOBEC3A 1079/4885APOBEC3G 721/4885KDM4E 4207/4885 |
| US-20250161307-A1 | PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE | SMOX, SRM, SMS | APOBEC3A 2514/4885APOBEC3G 3180/4885KDM4E 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.